{"protocolSection": {"identificationModule": {"nctId": "NCT03214380", "orgStudyIdInfo": {"id": "16314"}, "secondaryIdInfos": [{"id": "I8B-MC-ITRN", "type": "OTHER", "domain": "Eli Lilly and Company"}, {"id": "2015-005357-12", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Eli Lilly and Company", "class": "INDUSTRY"}, "briefTitle": "A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes", "officialTitle": "A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 2 Diabetes PRONTO-T2D", "acronym": "PRONTO-T2D"}, "statusModule": {"statusVerifiedDate": "2019-08-15", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-07-14", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-08-14", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-03-13", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-07-10", "studyFirstSubmitQcDate": "2017-07-10", "studyFirstPostDateStruct": {"date": "2017-07-11", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2020-03-12", "resultsFirstSubmitQcDate": "2020-03-12", "resultsFirstPostDateStruct": {"date": "2020-03-27", "type": "ACTUAL"}, "dispFirstSubmitDate": "2019-08-16", "dispFirstSubmitQcDate": "2019-08-16", "dispFirstPostDateStruct": {"date": "2019-08-20", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-03-12", "lastUpdatePostDateStruct": {"date": "2020-03-27", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Eli Lilly and Company", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to compare LY900014 to insulin lispro, both in combination with insulin glargine or insulin degludec, in participants with type 2 diabetes (T2D)."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 933, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "LY900014", "type": "EXPERIMENTAL", "description": "LY900014 given subcutaneously (SC) with each meal with either 100 U/mL (U-100) basal insulin glargine given SC once or twice daily or U-100 or 200 U/mL (U-200) insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.", "interventionNames": ["Drug: LY900014", "Drug: Insulin Glargine", "Drug: Insulin Degludec", "Drug: Metformin", "Drug: SGLT2 inhibitor"]}, {"label": "Insulin Lispro (Humalog)", "type": "ACTIVE_COMPARATOR", "description": "Insulin lispro given SC with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.", "interventionNames": ["Drug: Insulin Lispro", "Drug: Insulin Glargine", "Drug: Insulin Degludec", "Drug: Metformin", "Drug: SGLT2 inhibitor"]}, {"label": "LY900014 Maximum Extended Enrollment (MEE)", "type": "EXPERIMENTAL", "description": "LY900014 given subcutaneously (SC) with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.", "interventionNames": ["Drug: LY900014", "Drug: Insulin Glargine", "Drug: Insulin Degludec", "Drug: Metformin", "Drug: SGLT2 inhibitor"]}, {"label": "Insulin Lispro (Humalog) MEE", "type": "ACTIVE_COMPARATOR", "description": "Insulin lispro given SC with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.", "interventionNames": ["Drug: Insulin Lispro", "Drug: Insulin Glargine", "Drug: Insulin Degludec", "Drug: Metformin", "Drug: SGLT2 inhibitor"]}], "interventions": [{"type": "DRUG", "name": "LY900014", "description": "Administered SC", "armGroupLabels": ["LY900014", "LY900014 Maximum Extended Enrollment (MEE)"], "otherNames": ["Ultra-Rapid Lispro"]}, {"type": "DRUG", "name": "Insulin Lispro", "description": "Administered SC", "armGroupLabels": ["Insulin Lispro (Humalog)", "Insulin Lispro (Humalog) MEE"], "otherNames": ["Humalog"]}, {"type": "DRUG", "name": "Insulin Glargine", "description": "Administered SC", "armGroupLabels": ["Insulin Lispro (Humalog)", "Insulin Lispro (Humalog) MEE", "LY900014", "LY900014 Maximum Extended Enrollment (MEE)"]}, {"type": "DRUG", "name": "Insulin Degludec", "description": "Administered SC", "armGroupLabels": ["Insulin Lispro (Humalog)", "Insulin Lispro (Humalog) MEE", "LY900014", "LY900014 Maximum Extended Enrollment (MEE)"]}, {"type": "DRUG", "name": "Metformin", "description": "Administered orally.", "armGroupLabels": ["Insulin Lispro (Humalog)", "Insulin Lispro (Humalog) MEE", "LY900014", "LY900014 Maximum Extended Enrollment (MEE)"]}, {"type": "DRUG", "name": "SGLT2 inhibitor", "description": "Administered orally.", "armGroupLabels": ["Insulin Lispro (Humalog)", "Insulin Lispro (Humalog) MEE", "LY900014", "LY900014 Maximum Extended Enrollment (MEE)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26", "description": "Change from baseline in HbA1c was performed using mixed model repeated measures (MMRM) including fixed class effects of treatment, strata (pooled country, type of basal insulin, and number of prandial doses at study entry), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline value. The efficacy estimand included participant data when baseline and at least one post-baseline measurement were available prior to permanent discontinuation of study drug.", "timeFrame": "Baseline, Week 26"}], "secondaryOutcomes": [{"measure": "1-hour Postprandial Glucose (PPG) Excursion During Mixed-Meal Tolerance Test (MMTT) Efficacy Estimand", "description": "1-hour PPG excursion during MMTT uses the analysis of covariance (ANCOVA) model with strata (pooled country, type of basal insulin, number of prandial doses at study entry, and HbA1c stratum) and treatment as fixed effects and baseline as a covariate. The efficacy estimand included participant data when baseline and at least one post-baseline measurement were available prior to permanent discontinuation of study drug.", "timeFrame": "Week 26"}, {"measure": "2-hour PPG Excursion During MMTT Efficacy Estimand", "description": "2-hour PPG excursion during MMTT uses the ANCOVA model with strata (pooled country, type of basal insulin, number of prandial doses at study entry, and HbA1c stratum) and treatment as fixed effects and baseline as a covariate. The efficacy estimand included participant data when baseline and at least one post-baseline measurement were available prior to permanent discontinuation of study drug.", "timeFrame": "Week 26"}, {"measure": "Rate of Severe Hypoglycemia", "description": "Rate of severe hypoglycemia events per 100 years during a defined period was calculated by total number of severe hypoglycemia episodes within the period divided by the cumulative days on treatment from all participants within a treatment group \\*36525. Severe hypoglycemia is defined as an event requiring assistance of another person to administer carbohydrate, glucagon, or other resuscitative actions. During these episodes, the participant has an altered mental status and cannot assist in his or her own care, or may be semiconscious or unconscious, or experience com with or without seizures, and may require parenteral therapy.", "timeFrame": "Baseline through Week 26"}, {"measure": "Rate of Documented Symptomatic Hypoglycemia", "description": "Documented symptomatic hypoglycemia is an event during which typical symptoms of hypoglycemia are accompanied by blood glucose (BG) of \\<54 mg/dL \\[3.0 millimole per liter (mmol/L)\\]. The rate of documented symptomatic hypoglycemia was estimated by negative binomial model: number of episodes = treatment with log (treatment exposure in days/365.25) as an offset variable.", "timeFrame": "Baseline through Week 26"}, {"measure": "Change From Baseline in 1,5-Anhydroglucitol (1,5-AG) at Week 26", "description": "Change from baseline in 1,5-AG was analyzed using mixed model repeated measures (MMRM) including fixed class effects of treatment, strata (pooled country, type of basal insulin, HbA1c stratum and number of prandial doses at study entry), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline value. The analysis included data collected prior to permanent discontinuation of study drug.", "timeFrame": "Baseline, Week 26"}, {"measure": "Change From Baseline in 10-Point Self-Monitoring Blood Glucose (SMBG) Values at Week 26", "description": "Change from baseline in 10-point SMBG values was analyzed using mixed model repeated measures (MMRM) including fixed class effects of treatment, strata (pooled country, type of basal insulin, HbA1c stratum and number of prandial doses at study entry), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline value. The efficacy estimand included participant data when baseline and at least one post-baseline measurement prior to permanent discontinuation of study drug.", "timeFrame": "Baseline, Week 26"}, {"measure": "Change From Baseline in Insulin Dose at Week 26", "description": "Change from baseline in insulin dose was analyzed using mixed model repeated measures (MMRM) including fixed class effects of treatment, strata (pooled country, type of basal insulin, HbA1c stratum and number of prandial doses at study entry), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline value. The analysis included data prior to permanent discontinuation of study drug.", "timeFrame": "Baseline, Week 26"}, {"measure": "Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) Regimen Inconvenience Domain Score at Week 26", "description": "ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. The questionnaire measures satisfaction from the following 5 domains: Inconvenience of Regimen, Lifestyle Flexibility, Glycemic Control, Hypoglycemic Control, and Insulin Delivery Device. Data presented are the transformed overall score on a scale of 0-100, where higher scores indicate better treatment satisfaction.\n\nChange from baseline in ITSQ regimen inconvenience domain score was calculated using the ANCOVA model with strata (pooled country, type of basal insulin, number of prandial doses at study entry, and HbA1c stratum), and treatment as fixed effects and baseline as covariate. The analysis included data prior to permanent discontinuation of study drug.", "timeFrame": "Baseline, Week 26"}, {"measure": "Change From Baseline in ITSQ Lifestyle Flexibility Domain Score at Week 26", "description": "ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. The questionnaire measures satisfaction from the following 5 domains: Inconvenience of Regimen, Lifestyle Flexibility, Glycemic Control, Hypoglycemic Control, and Insulin Delivery Device. Data presented are the transformed overall score on a scale of 0-100, where higher scores indicate better treatment satisfaction.\n\nChange from baseline in ITSQ lifestyle flexibility domain score was calculated using the ANCOVA model with strata (pooled country, type of basal insulin, number of prandial doses at study entry, and HbA1c stratum), and treatment as fixed effects and baseline as covariate. The analysis included data prior to permanent discontinuation of study drug.", "timeFrame": "Baseline, Week 26"}, {"measure": "Number of Participants With HbA1c <7%", "description": "Number of participants with HbA1c \\<7% at Week 26.", "timeFrame": "Week 26"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Have been diagnosed (clinically) with T2D, based on the World Health Organization (WHO) classification for at least 1 year prior to screening.\n* Have been treated for at least 90 days prior to screening with:\n\n  * Basal insulin (insulin glargine U-100 \\[Basaglar/Abasaglar or LANTUS\\] or U-300, insulin detemir, insulin degludec U-100 or U-200, or neutral protamine Hagedorn \\[NPH\\] insulin) in combination with at least 1 prandial injection of bolus insulin (insulin lispro U-100 or U-200, insulin aspart, insulin glulisine, or regular insulin) Or\n  * Premixed analog or human insulin regimens with any basal and bolus insulin combination injected at least twice daily\n* Participants may be treated with up to 3 of the following oral antihyperglycemic medications (OAMs) in accordance with local regulations:\n\n  * Metformin\n  * Dipeptidyl peptidase-4 (DPP-4) inhibitor\n  * Sodium glucose cotransporter 2 (SGLT2) inhibitor\n  * Sulfonylurea\n  * Meglitinide\n  * Alpha-glucoside inhibitor\n* Have an HbA1c value between \u22657.0 and \u226410.0%, according to the central laboratory at the time of screening.\n* Have a body mass index (BMI) of \u226445.0 kilograms per meter squared at screening.\n\nExclusion Criteria:\n\n* Have been diagnosed, at any time, with type 1 diabetes (T1D) or Latent Autoimmune Diabetes in Adults.\n* Have hypoglycemia unawareness as judged by the investigator.\n* Have had any episode of severe hypoglycemia within the 6 months prior to screening.\n* Have had 1 or more episodes of diabetic ketoacidosis or hyperglycemic hyperosmolar state within the 6 months prior to screening.\n* Have used thiazolidinediones, Glucagon-Like Peptide 1 (GLP-1) receptor agonist, or pramlintide within 90 days prior to screening.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", "affiliation": "Eli Lilly and Company", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Valley Research", "city": "Fresno", "state": "California", "zip": "93720", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Diabetes and Endocrine Associates", "city": "La Mesa", "state": "California", "zip": "91942", "country": "United States", "geoPoint": {"lat": 32.76783, "lon": -117.02308}}, {"facility": "First Valley Medical Group", "city": "Lancaster", "state": "California", "zip": "93534", "country": "United States", "geoPoint": {"lat": 34.69804, "lon": -118.13674}}, {"facility": "National Research Institute", "city": "Los Angeles", "state": "California", "zip": "90057", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Care Access Research", "city": "Santa Clarita", "state": "California", "zip": "91321", "country": "United States", "geoPoint": {"lat": 34.39166, "lon": -118.54259}}, {"facility": "Encompass Clinical Research", "city": "Spring Valley", "state": "California", "zip": "91978", "country": "United States", "geoPoint": {"lat": 32.74477, "lon": -116.99892}}, {"facility": "University Clinical Investigators, Inc.", "city": "Tustin", "state": "California", "zip": "92780", "country": "United States", "geoPoint": {"lat": 33.74585, "lon": -117.82617}}, {"facility": "ALL Medical Research, LLC", "city": "Cooper City", "state": "Florida", "zip": "33024", "country": "United States", "geoPoint": {"lat": 26.05731, "lon": -80.27172}}, {"facility": "The Center For Diabetes & Endocrine Care", "city": "Fort Lauderdale", "state": "Florida", "zip": "33312", "country": "United States", "geoPoint": {"lat": 26.12231, "lon": -80.14338}}, {"facility": "East Coast Institute For Research", "city": "Jacksonville", "state": "Florida", "zip": "32216", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "Sun Coast Clinical Research, Inc", "city": "New Port Richey", "state": "Florida", "zip": "34652", "country": "United States", "geoPoint": {"lat": 28.24418, "lon": -82.71927}}, {"facility": "East West Medical Institute", "city": "Honolulu", "state": "Hawaii", "zip": "96814", "country": "United States", "geoPoint": {"lat": 21.30694, "lon": -157.85833}}, {"facility": "Elite Clinical Trials LLLP", "city": "Blackfoot", "state": "Idaho", "zip": "83221", "country": "United States", "geoPoint": {"lat": 43.19047, "lon": -112.34498}}, {"facility": "Northwest Clinical Trials", "city": "Boise", "state": "Idaho", "zip": "83704", "country": "United States", "geoPoint": {"lat": 43.6135, "lon": -116.20345}}, {"facility": "Rocky Mountain Diabetes and Osteoporosis Center", "city": "Idaho Falls", "state": "Idaho", "zip": "83404", "country": "United States", "geoPoint": {"lat": 43.46658, "lon": -112.03414}}, {"facility": "Prairie Education and Research Cooperative", "city": "Springfield", "state": "Illinois", "zip": "62711", "country": "United States", "geoPoint": {"lat": 39.80172, "lon": -89.64371}}, {"facility": "Iderc, P.L.C.", "city": "West Des Moines", "state": "Iowa", "zip": "50265", "country": "United States", "geoPoint": {"lat": 41.57721, "lon": -93.71133}}, {"facility": "University of Kansas Medical Center", "city": "Kansas City", "state": "Kansas", "zip": "66160", "country": "United States", "geoPoint": {"lat": 39.11417, "lon": -94.62746}}, {"facility": "Cotton O'Neil Diabetes and Endocrinology Center", "city": "Kansas City", "state": "Kansas", "zip": "66606", "country": "United States", "geoPoint": {"lat": 39.11417, "lon": -94.62746}}, {"facility": "Palm Research Center", "city": "Las Vegas", "state": "Nevada", "zip": "89128", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Palm Research Center", "city": "Las Vegas", "state": "Nevada", "zip": "89148", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Manhattan Medical Research", "city": "New York", "state": "New York", "zip": "10016", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Aventiv Research", "city": "Columbus", "state": "Ohio", "zip": "43213", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Heritage Valley Medical Group, Inc.", "city": "Beaver", "state": "Pennsylvania", "zip": "15009", "country": "United States", "geoPoint": {"lat": 40.69534, "lon": -80.30478}}, {"facility": "Partners in Nephrology & Endocrinology", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15224", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Texas Diabetes and Endocrinology", "city": "Austin", "state": "Texas", "zip": "78731-4309", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Texas Diabetes and Endocrinology-Austin South", "city": "Austin", "state": "Texas", "zip": "78749", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Dallas Diabetes Endocrine Center", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Consano Clinical Research", "city": "Shavano Park", "state": "Texas", "zip": "78231", "country": "United States", "geoPoint": {"lat": 29.58495, "lon": -98.55252}}, {"facility": "Progressive Clinical Research", "city": "Bountiful", "state": "Utah", "zip": "84010", "country": "United States", "geoPoint": {"lat": 40.88939, "lon": -111.88077}}, {"facility": "Private: Dr. Larry Stonesifer", "city": "Federal Way", "state": "Washington", "zip": "98003", "country": "United States", "geoPoint": {"lat": 47.32232, "lon": -122.31262}}, {"facility": "Rainier Clinical Research Center", "city": "Renton", "state": "Washington", "zip": "98057", "country": "United States", "geoPoint": {"lat": 47.48288, "lon": -122.21707}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Caba", "state": "Buenos Aires", "zip": "1425", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Caba", "state": "Buenos Aires", "zip": "C1013AAB", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Caba", "state": "Buenos Aires", "zip": "C1179AAB", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Ciudad Autonoma de Buenos Aire", "state": "Buenos Aires", "zip": "1408", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Ciudad Autonoma de Buenos Aire", "state": "Buenos Aires", "zip": "C1056ABJ", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Ciudad Autonoma de Buenos Aire", "state": "Buenos Aires", "zip": "C1204AAD", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Mar del Plata", "state": "Buenos Aires", "zip": "B7600FZN", "country": "Argentina", "geoPoint": {"lat": -38.00228, "lon": -57.55754}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Keswick", "state": "South Australia", "zip": "5035", "country": "Australia", "geoPoint": {"lat": -34.97487, "lon": 149.27077}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Oaklands Park", "state": "South Australia", "zip": "5046", "country": "Australia", "geoPoint": {"lat": -35.01408, "lon": 138.53841}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Box Hill", "state": "Victoria", "zip": "3128", "country": "Australia", "geoPoint": {"lat": -37.81887, "lon": 145.12545}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Geelong", "state": "Victoria", "zip": "3220", "country": "Australia", "geoPoint": {"lat": -38.14711, "lon": 144.36069}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Fremantle", "state": "Western Australia", "zip": "6959", "country": "Australia", "geoPoint": {"lat": -32.05629, "lon": 115.74565}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Krnov", "zip": "79401", "country": "Czechia", "geoPoint": {"lat": 50.08967, "lon": 17.70385}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Pardubice", "zip": "53002", "country": "Czechia", "geoPoint": {"lat": 50.04075, "lon": 15.77659}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Praha", "zip": "104 00", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Praha", "zip": "149 00", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Praha", "zip": "181 00", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Bad Mergentheim", "state": "Baden-W\u00fcrttemberg", "zip": "97980", "country": "Germany", "geoPoint": {"lat": 49.4925, "lon": 9.77361}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Falkensee", "state": "Brandenburg", "zip": "14612", "country": "Germany", "geoPoint": {"lat": 52.56014, "lon": 13.0927}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Pohlheim", "state": "Hessen", "zip": "35415", "country": "Germany"}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "M\u00fcnster", "state": "Nordrhein-Westfalen", "zip": "48145", "country": "Germany", "geoPoint": {"lat": 51.96236, "lon": 7.62571}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Mayen", "state": "Rheinland-Pfalz", "zip": "56727", "country": "Germany", "geoPoint": {"lat": 50.32797, "lon": 7.22277}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Saint Ingbert-Oberw\u00fcrzbach", "state": "Saarland", "zip": "66386", "country": "Germany"}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Magdeburg", "state": "Sachsen-Anhalt", "zip": "39120", "country": "Germany", "geoPoint": {"lat": 52.12773, "lon": 11.62916}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Oldenburg", "state": "Schleswig-Holstein", "zip": "23758", "country": "Germany", "geoPoint": {"lat": 53.14118, "lon": 8.21467}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Hamburg", "zip": "22607", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Budapest", "zip": "1089", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Budapest", "zip": "1139", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician", "city": "Budapest", "zip": "1213", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Nagykanizsa", "zip": "8800", "country": "Hungary", "geoPoint": {"lat": 46.45347, "lon": 16.99104}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Ahmedabad", "state": "Gujarat", "zip": "380015", "country": "India", "geoPoint": {"lat": 23.02579, "lon": 72.58727}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Ahmedabad", "state": "Gujarat", "zip": "380015", "country": "India", "geoPoint": {"lat": 23.02579, "lon": 72.58727}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Ahmedabad", "state": "Gujarat", "zip": "380016", "country": "India", "geoPoint": {"lat": 23.02579, "lon": 72.58727}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Bangalore", "state": "Karnataka", "zip": "560017", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Bangalore", "state": "Karnataka", "zip": "560054", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Pune", "state": "Maharashtra", "zip": "411004", "country": "India", "geoPoint": {"lat": 18.51957, "lon": 73.85535}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Pune", "state": "Maharashtra", "zip": "411011", "country": "India", "geoPoint": {"lat": 18.51957, "lon": 73.85535}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Mumbai", "state": "Maharshtra", "zip": "400012", "country": "India", "geoPoint": {"lat": 19.07283, "lon": 72.88261}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Jaipur", "state": "Rajasthan", "zip": "302017", "country": "India", "geoPoint": {"lat": 26.91962, "lon": 75.78781}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Chennai", "state": "Tamil Nadu", "zip": "600086", "country": "India", "geoPoint": {"lat": 13.08784, "lon": 80.27847}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Hyderabad", "state": "Telangana", "zip": "500012", "country": "India", "geoPoint": {"lat": 17.38405, "lon": 78.45636}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Hyderabad", "state": "Telangana", "zip": "500072", "country": "India", "geoPoint": {"lat": 17.38405, "lon": 78.45636}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Palmero", "zip": "90127", "country": "Italy", "geoPoint": {"lat": 44.96989, "lon": 7.55434}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Sesto San Giovanni", "zip": "20099", "country": "Italy", "geoPoint": {"lat": 45.53329, "lon": 9.22585}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Chiba", "zip": "277-0825", "country": "Japan", "geoPoint": {"lat": 35.6, "lon": 140.11667}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Fukuoka", "zip": "815-8555", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Fukuoka", "zip": "830-8543", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician", "city": "Hy\u014dgo", "zip": "661-0002", "country": "Japan"}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Kanagawa", "zip": "235-0045", "country": "Japan", "geoPoint": {"lat": 37.58333, "lon": 139.91667}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Kanagawa", "zip": "247-0056", "country": "Japan", "geoPoint": {"lat": 37.58333, "lon": 139.91667}}, {"facility": "\"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.\"", "city": "Kumamoto", "zip": "862-0976", "country": "Japan", "geoPoint": {"lat": 32.80589, "lon": 130.69182}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Miyazaki", "zip": "880-0034", "country": "Japan", "geoPoint": {"lat": 31.91667, "lon": 131.41667}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Naka", "zip": "311-0113", "country": "Japan", "geoPoint": {"lat": 36.05, "lon": 140.16667}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Sapporo", "zip": "060-0001", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Sapporo", "zip": "060-0062", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Sasebo", "zip": "857-1195", "country": "Japan", "geoPoint": {"lat": 33.16832, "lon": 129.72501}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Sendai", "zip": "980-0021", "country": "Japan", "geoPoint": {"lat": 38.26667, "lon": 140.86667}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "Tama", "zip": "206-0033", "country": "Japan"}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Tokyo", "zip": "103-0027", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Tokyo", "zip": "1030002", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Tokyo", "zip": "143-0015", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Tokyo", "zip": "160 0022", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Yamato", "zip": "242-0004", "country": "Japan"}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "\u014cita", "zip": "870-0039", "country": "Japan", "geoPoint": {"lat": 33.23333, "lon": 131.6}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "\u014csaka", "zip": "530-0001", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "city": "\u014csaka", "zip": "534-0021", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Bucheon", "state": "Gyeonggi-do", "zip": "14647", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Ansan-si", "zip": "15355", "country": "Korea, Republic of", "geoPoint": {"lat": 37.32361, "lon": 126.82194}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Daegu", "zip": "41931", "country": "Korea, Republic of", "geoPoint": {"lat": 35.87028, "lon": 128.59111}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Daejeon", "zip": "35233", "country": "Korea, Republic of", "geoPoint": {"lat": 36.32139, "lon": 127.41972}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Gangwon-do", "zip": "24289", "country": "Korea, Republic of"}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Gangwon-do", "zip": "26426", "country": "Korea, Republic of"}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Seoul", "zip": "01830", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Seoul", "zip": "02841", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Seoul", "zip": "03181", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Seoul", "zip": "05278", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Seoul", "zip": "06351", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Seoul", "zip": "06591", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Seoul", "zip": "07061", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Seoul", "zip": "08308", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Jalisco", "zip": "44650", "country": "Mexico"}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Monterrey", "zip": "64460", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Zapopan", "zip": "45030", "country": "Mexico", "geoPoint": {"lat": 20.72356, "lon": -103.38479}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Zapopan", "zip": "45116", "country": "Mexico", "geoPoint": {"lat": 20.72356, "lon": -103.38479}}, {"facility": "Centro de Endocrinologia y Nutricion del Turabo", "city": "Caguas", "zip": "00726", "country": "Puerto Rico", "geoPoint": {"lat": 18.23412, "lon": -66.0485}}, {"facility": "Manati Center for Clinical Research Inc", "city": "Manati", "zip": "00674", "country": "Puerto Rico", "geoPoint": {"lat": 18.42745, "lon": -66.49212}}, {"facility": "Ponce School of Medicine CAIMED Center", "city": "Ponce", "zip": "00716", "country": "Puerto Rico", "geoPoint": {"lat": 18.01108, "lon": -66.61406}}, {"facility": "Research and Cardiovascular Corp.", "city": "Ponce", "zip": "00717-1332", "country": "Puerto Rico", "geoPoint": {"lat": 18.01108, "lon": -66.61406}}, {"facility": "GCM Medical Group PSC", "city": "San Juan", "zip": "00917", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Arkhangel'sk", "zip": "163045", "country": "Russian Federation", "geoPoint": {"lat": 64.5401, "lon": 40.5433}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Kursk", "zip": "305014", "country": "Russian Federation", "geoPoint": {"lat": 51.73733, "lon": 36.18735}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Moscow", "zip": "119435", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Moscow", "zip": "123182", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Saint Petersburg", "zip": "195257", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Saratov", "zip": "410053", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Ko\u0161ice", "state": "Slovak Republic", "zip": "04012", "country": "Slovakia", "geoPoint": {"lat": 48.71395, "lon": 21.25808}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Malacky", "zip": "90101", "country": "Slovakia", "geoPoint": {"lat": 48.43604, "lon": 17.02188}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Nove Mesto nad Vahom", "zip": "91501", "country": "Slovakia", "geoPoint": {"lat": 48.75763, "lon": 17.8309}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "P\u00fachov", "zip": "02001", "country": "Slovakia", "geoPoint": {"lat": 49.12494, "lon": 18.32597}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Ro\u017e\u0148ava", "zip": "048 01", "country": "Slovakia", "geoPoint": {"lat": 48.66009, "lon": 20.53758}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Lleida", "zip": "25198", "country": "Spain", "geoPoint": {"lat": 41.61674, "lon": 0.62218}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "M\u00e1laga", "zip": "29006", "country": "Spain", "geoPoint": {"lat": 36.72016, "lon": -4.42034}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Sevilla", "zip": "41003", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Sevilla", "zip": "41010", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Taichung", "zip": "40201", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Taipei", "zip": "10507", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Taipei", "zip": "11031", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Taipei", "zip": "23148", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Yongkang", "zip": "71004", "country": "Taiwan"}]}, "referencesModule": {"references": [{"pmid": "35781789", "type": "DERIVED", "citation": "Zhang Q, Chigutsa F, Chang AM. Efficacy and Safety of Ultra-Rapid Lispro in Younger and Older Patients with Type 2 Diabetes: Randomized Double-Blind PRONTO-T2D Study. Diabetes Ther. 2022 Aug;13(8):1547-1557. doi: 10.1007/s13300-022-01290-4. Epub 2022 Jul 4."}, {"pmid": "32728833", "type": "DERIVED", "citation": "Jinnouchi H, Imori M, Nishiyama H, Imaoka T. Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog(R) in Japanese Patients With Type 2 Diabetes: PRONTO-T2D Subpopulation Analysis. Diabetes Ther. 2020 Sep;11(9):2075-2088. doi: 10.1007/s13300-020-00890-2. Epub 2020 Jul 29."}, {"pmid": "32616612", "type": "DERIVED", "citation": "Blevins T, Zhang Q, Frias JP, Jinnouchi H, Chang AM; PRONTO-T2D Investigators. Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D. Diabetes Care. 2020 Dec;43(12):2991-2998. doi: 10.2337/dc19-2550. Epub 2020 Jul 2."}], "seeAlsoLinks": [{"label": "A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes (PRONTO-T2D)", "url": "https://www.lillytrialguide.com/en-US/studies/type-2-diabetes/ITRN#?postal="}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.", "infoTypes": ["STUDY_PROTOCOL", "SAP", "CSR"], "timeFrame": "Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.", "accessCriteria": "A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.", "url": "https://vivli.org/"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The purpose of the Lead-in Period was to titrate basal insulin prior to randomization. Participants were then randomized to receive Insulin lispro (Humalog) or LY900014 in the Treatment Period (Period 2).", "groups": [{"id": "FG000", "title": "Insulin Lispro (Humalog) Lead-In", "description": "100 U/mL Insulin lispro given SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}, {"id": "FG001", "title": "Insulin Lispro (Humalog)", "description": "100 U/mL Insulin lispro given SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}, {"id": "FG002", "title": "LY900014", "description": "100 U/mL LY900014 SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}, {"id": "FG003", "title": "Insulin Lispro (Humalog) Lead-In Maximum Extended Enrollment", "description": "100 U/mL Insulin lispro (Humalog) SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}, {"id": "FG004", "title": "Insulin Lispro (Humalog) Maximum Extended Enrollment (MEE)", "description": "100 U/mL Insulin lispro (Humalog) SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}, {"id": "FG005", "title": "LY900014 (MEE)", "description": "100 U/mL LY900014 SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}], "periods": [{"title": "Lead-in", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "750"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "183"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Received at Least 1 Dose Lead-in Insulin", "achievements": [{"groupId": "FG000", "numSubjects": "750"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "183"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "673"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "164"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "77"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "19"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Eligibility Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "41"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "14"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Family Emergency", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Natural Disaster", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Non Compliance", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Participant Schedule", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Treatment Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Participants received Insulin Lispro during Lead-in Period.", "numSubjects": "0"}, {"groupId": "FG001", "comment": "Participants were randomized to either LY900014 or Insulin lispro for Intensive Treatment Period.", "numSubjects": "337"}, {"groupId": "FG002", "comment": "Participants were randomized to either LY900014 or Insulin lispro for Intensive Treatment Period.", "numSubjects": "336"}, {"groupId": "FG003", "comment": "Participants received Insulin Lispro during Lead-in Period.", "numSubjects": "0"}, {"groupId": "FG004", "comment": "Participants were randomized to either LY900014 or Insulin lispro for Intensive Treatment Period.", "numSubjects": "82"}, {"groupId": "FG005", "comment": "Participants were randomized to either LY900014 or Insulin lispro for Intensive Treatment Period.", "numSubjects": "82"}]}, {"type": "Received at Least 1 Dose of Study Drug", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "337"}, {"groupId": "FG002", "numSubjects": "336"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "82"}, {"groupId": "FG005", "numSubjects": "82"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "319"}, {"groupId": "FG002", "numSubjects": "320"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "73"}, {"groupId": "FG005", "numSubjects": "71"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "18"}, {"groupId": "FG002", "numSubjects": "16"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "11"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Non-Compliance with Study Drug", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "7"}, {"groupId": "FG005", "numSubjects": "11"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Participant schedule", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Treatment Interruption", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All randomized participants.", "groups": [{"id": "BG000", "title": "Insulin Lispro (Humalog)", "description": "Insulin lispro given SC with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}, {"id": "BG001", "title": "LY900014", "description": "LY900014 given subcutaneously (SC) with each meal with either 100 U/mL (U-100) basal insulin glargine given SC once or twice daily or U-100 or 200 U/mL (U-200) insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}, {"id": "BG002", "title": "Insulin Lispro (Humalog) MEE", "description": "Insulin lispro given SC with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}, {"id": "BG003", "title": "LY900014 Maximum Extended Enrollment (MEE)", "description": "LY900014 given subcutaneously (SC) with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "337"}, {"groupId": "BG001", "value": "336"}, {"groupId": "BG002", "value": "82"}, {"groupId": "BG003", "value": "82"}, {"groupId": "BG004", "value": "837"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "61.0", "spread": "9.2"}, {"groupId": "BG001", "value": "60.2", "spread": "9.4"}, {"groupId": "BG002", "value": "56.6", "spread": "9.4"}, {"groupId": "BG003", "value": "57.2", "spread": "10.1"}, {"groupId": "BG004", "value": "59.9", "spread": "9.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "162"}, {"groupId": "BG001", "value": "152"}, {"groupId": "BG002", "value": "47"}, {"groupId": "BG003", "value": "27"}, {"groupId": "BG004", "value": "388"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "175"}, {"groupId": "BG001", "value": "184"}, {"groupId": "BG002", "value": "35"}, {"groupId": "BG003", "value": "55"}, {"groupId": "BG004", "value": "449"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "4"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "81"}, {"groupId": "BG001", "value": "83"}, {"groupId": "BG002", "value": "70"}, {"groupId": "BG003", "value": "69"}, {"groupId": "BG004", "value": "303"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "1"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "30"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "229"}, {"groupId": "BG001", "value": "233"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "13"}, {"groupId": "BG004", "value": "487"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "11"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "1"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"title": "Argentina", "categories": [{"measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "56"}]}]}, {"title": "Puerto Rico", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "14"}]}]}, {"title": "Hungary", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "28"}]}]}, {"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "95"}, {"groupId": "BG001", "value": "92"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "187"}]}]}, {"title": "Czechia", "categories": [{"measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "40"}]}]}, {"title": "Japan", "categories": [{"measurements": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "93"}]}]}, {"title": "India", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "44"}, {"groupId": "BG004", "value": "100"}]}]}, {"title": "Russia", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "12"}, {"groupId": "BG004", "value": "50"}]}]}, {"title": "Spain", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "30"}]}]}, {"title": "South Korea", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "21"}, {"groupId": "BG003", "value": "16"}, {"groupId": "BG004", "value": "69"}]}]}, {"title": "Taiwan", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "9"}, {"groupId": "BG004", "value": "33"}]}]}, {"title": "Italy", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "9"}]}]}, {"title": "Mexico", "categories": [{"measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "45"}]}]}, {"title": "Slovakia", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "28"}]}]}, {"title": "Australia", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "15"}]}]}, {"title": "Germany", "categories": [{"measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "40"}]}]}]}, {"title": "Hemoglobin A1c", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of HbA1c", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.31", "spread": "0.71"}, {"groupId": "BG001", "value": "7.27", "spread": "0.68"}, {"groupId": "BG002", "value": "7.53", "spread": "0.69"}, {"groupId": "BG003", "value": "7.67", "spread": "0.89"}, {"groupId": "BG004", "value": "7.35", "spread": "0.73"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26", "description": "Change from baseline in HbA1c was performed using mixed model repeated measures (MMRM) including fixed class effects of treatment, strata (pooled country, type of basal insulin, and number of prandial doses at study entry), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline value. The efficacy estimand included participant data when baseline and at least one post-baseline measurement were available prior to permanent discontinuation of study drug.", "populationDescription": "All randomized participants with baseline and at least 1 post-baseline HbA1c data. As pre-specified in the analysis plan, outcome measures will not be reported for the Maximum Extended Enrollment (MEE) arms/groups but only for the main global study arms/groups.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of HbA1c", "timeFrame": "Baseline, Week 26", "groups": [{"id": "OG000", "title": "Insulin Lispro (Humalog)", "description": "Insulin lispro given SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}, {"id": "OG001", "title": "LY900014", "description": "LY900014 given subcutaneously (SC) with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "335"}, {"groupId": "OG001", "value": "334"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.43", "spread": "0.042"}, {"groupId": "OG001", "value": "-0.38", "spread": "0.042"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "NON_INFERIORITY", "nonInferiorityComment": "Non-inferiority Margin = 0.4 for HbA1c", "paramType": "Least Square Mean Difference (LSMean)", "paramValue": "0.06", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.05", "ciUpperLimit": "0.16"}]}, {"type": "SECONDARY", "title": "1-hour Postprandial Glucose (PPG) Excursion During Mixed-Meal Tolerance Test (MMTT) Efficacy Estimand", "description": "1-hour PPG excursion during MMTT uses the analysis of covariance (ANCOVA) model with strata (pooled country, type of basal insulin, number of prandial doses at study entry, and HbA1c stratum) and treatment as fixed effects and baseline as a covariate. The efficacy estimand included participant data when baseline and at least one post-baseline measurement were available prior to permanent discontinuation of study drug.", "populationDescription": "All randomized participants with baseline and at least one post-baseline 1-hour PPG excursion data. As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "milligrams per deciliter (mg/dL)", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Insulin Lispro (Humalog)", "description": "Insulin lispro given SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}, {"id": "OG001", "title": "LY900014", "description": "LY900014 given subcutaneously (SC) with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "307"}, {"groupId": "OG001", "value": "304"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "74.9", "spread": "3.60"}, {"groupId": "OG001", "value": "63.1", "spread": "3.60"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-11.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-18.1", "ciUpperLimit": "-5.5"}]}, {"type": "SECONDARY", "title": "2-hour PPG Excursion During MMTT Efficacy Estimand", "description": "2-hour PPG excursion during MMTT uses the ANCOVA model with strata (pooled country, type of basal insulin, number of prandial doses at study entry, and HbA1c stratum) and treatment as fixed effects and baseline as a covariate. The efficacy estimand included participant data when baseline and at least one post-baseline measurement were available prior to permanent discontinuation of study drug.", "populationDescription": "All randomized participants with baseline and at least one post-baseline 2-hour PPG excursion data. As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Insulin Lispro (Humalog)", "description": "Insulin lispro given SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}, {"id": "OG001", "title": "LY900014", "description": "LY900014 given subcutaneously (SC) with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "306"}, {"groupId": "OG001", "value": "305"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "97.8", "spread": "4.50"}, {"groupId": "OG001", "value": "80.4", "spread": "4.50"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-17.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-25.3", "ciUpperLimit": "-9.5"}]}, {"type": "SECONDARY", "title": "Rate of Severe Hypoglycemia", "description": "Rate of severe hypoglycemia events per 100 years during a defined period was calculated by total number of severe hypoglycemia episodes within the period divided by the cumulative days on treatment from all participants within a treatment group \\*36525. Severe hypoglycemia is defined as an event requiring assistance of another person to administer carbohydrate, glucagon, or other resuscitative actions. During these episodes, the participant has an altered mental status and cannot assist in his or her own care, or may be semiconscious or unconscious, or experience com with or without seizures, and may require parenteral therapy.", "populationDescription": "All randomized participants with evaluable hypoglycemic data. As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Events per 100 participant years", "timeFrame": "Baseline through Week 26", "groups": [{"id": "OG000", "title": "Insulin Lispro (Humalog)", "description": "Insulin lispro given SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}, {"id": "OG001", "title": "LY900014", "description": "LY900014 given subcutaneously (SC) with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "337"}, {"groupId": "OG001", "value": "336"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.19"}, {"groupId": "OG001", "value": "2.44"}]}]}]}, {"type": "SECONDARY", "title": "Rate of Documented Symptomatic Hypoglycemia", "description": "Documented symptomatic hypoglycemia is an event during which typical symptoms of hypoglycemia are accompanied by blood glucose (BG) of \\<54 mg/dL \\[3.0 millimole per liter (mmol/L)\\]. The rate of documented symptomatic hypoglycemia was estimated by negative binomial model: number of episodes = treatment with log (treatment exposure in days/365.25) as an offset variable.", "populationDescription": "All randomized participants with evaluable hypoglycemic data. As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Events per participant per 30 days/year", "timeFrame": "Baseline through Week 26", "groups": [{"id": "OG000", "title": "Insulin Lispro (Humalog)", "description": "Insulin lispro given SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}, {"id": "OG001", "title": "LY900014", "description": "LY900014 given subcutaneously (SC) with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "337"}, {"groupId": "OG001", "value": "336"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.34", "spread": "0.164"}, {"groupId": "OG001", "value": "2.21", "spread": "0.318"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in 1,5-Anhydroglucitol (1,5-AG) at Week 26", "description": "Change from baseline in 1,5-AG was analyzed using mixed model repeated measures (MMRM) including fixed class effects of treatment, strata (pooled country, type of basal insulin, HbA1c stratum and number of prandial doses at study entry), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline value. The analysis included data collected prior to permanent discontinuation of study drug.", "populationDescription": "All randomized participants with baseline and at least one post-baseline 1,5-AG data. As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "milligram per liter (mg/L)", "timeFrame": "Baseline, Week 26", "groups": [{"id": "OG000", "title": "Insulin Lispro (Humalog)", "description": "Insulin lispro given SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}, {"id": "OG001", "title": "LY900014", "description": "LY900014 given subcutaneously (SC) with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "334"}, {"groupId": "OG001", "value": "331"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.15", "spread": "0.234"}, {"groupId": "OG001", "value": "1.99", "spread": "0.235"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in 10-Point Self-Monitoring Blood Glucose (SMBG) Values at Week 26", "description": "Change from baseline in 10-point SMBG values was analyzed using mixed model repeated measures (MMRM) including fixed class effects of treatment, strata (pooled country, type of basal insulin, HbA1c stratum and number of prandial doses at study entry), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline value. The efficacy estimand included participant data when baseline and at least one post-baseline measurement prior to permanent discontinuation of study drug.", "populationDescription": "All randomized participants with baseline and at least one post-baseline SMBG data. As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline, Week 26", "groups": [{"id": "OG000", "title": "Insulin Lispro (Humalog)", "description": "Insulin lispro given SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}, {"id": "OG001", "title": "LY900014", "description": "LY900014 given subcutaneously (SC) with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "276"}, {"groupId": "OG001", "value": "270"}]}], "classes": [{"title": "Morning Premeal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "276"}, {"groupId": "OG001", "value": "270"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "2.72"}, {"groupId": "OG001", "value": "1.5", "spread": "2.74"}]}]}, {"title": "Morning 1-hour Postmeal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "271"}, {"groupId": "OG001", "value": "269"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.0", "spread": "3.44"}, {"groupId": "OG001", "value": "-14.1", "spread": "3.44"}]}]}, {"title": "Morning 2-hour Postmeal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "268"}, {"groupId": "OG001", "value": "268"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6", "spread": "3.38"}, {"groupId": "OG001", "value": "-14.9", "spread": "3.38"}]}]}, {"title": "Midday Premeal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "273"}, {"groupId": "OG001", "value": "268"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.4", "spread": "2.83"}, {"groupId": "OG001", "value": "4.1", "spread": "2.84"}]}]}, {"title": "Midday 1-hour Postmeal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "266"}, {"groupId": "OG001", "value": "267"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.0", "spread": "3.48"}, {"groupId": "OG001", "value": "-2.0", "spread": "3.47"}]}]}, {"title": "Midday 2-hour Postmeal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "265"}, {"groupId": "OG001", "value": "268"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.2", "spread": "3.28"}, {"groupId": "OG001", "value": "-6.5", "spread": "3.27"}]}]}, {"title": "Evening Premeal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "271"}, {"groupId": "OG001", "value": "269"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.0", "spread": "3.38"}, {"groupId": "OG001", "value": "10.1", "spread": "3.38"}]}]}, {"title": "Evening 1-hour Postmeal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "264"}, {"groupId": "OG001", "value": "267"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.1", "spread": "3.24"}, {"groupId": "OG001", "value": "-3.0", "spread": "3.27"}]}]}, {"title": "Evening 2-hour Postmeal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "266"}, {"groupId": "OG001", "value": "266"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.2", "spread": "3.68"}, {"groupId": "OG001", "value": "-2.1", "spread": "3.73"}]}]}, {"title": "Bedtime", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "244"}, {"groupId": "OG001", "value": "252"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.4", "spread": "4.00"}, {"groupId": "OG001", "value": "-2.2", "spread": "4.02"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Insulin Dose at Week 26", "description": "Change from baseline in insulin dose was analyzed using mixed model repeated measures (MMRM) including fixed class effects of treatment, strata (pooled country, type of basal insulin, HbA1c stratum and number of prandial doses at study entry), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline value. The analysis included data prior to permanent discontinuation of study drug.", "populationDescription": "All randomized participants with baseline and at least one post-baseline basal insulin dose data. As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Units (U)", "timeFrame": "Baseline, Week 26", "groups": [{"id": "OG000", "title": "Insulin Lispro (Humalog)", "description": "Insulin lispro given SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}, {"id": "OG001", "title": "LY900014", "description": "LY900014 given subcutaneously (SC) with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "330"}, {"groupId": "OG001", "value": "330"}]}], "classes": [{"title": "Basal Insulin Dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "323"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.2", "spread": "0.82"}, {"groupId": "OG001", "value": "4.6", "spread": "0.81"}]}]}, {"title": "Prandial Insulin Dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "330"}, {"groupId": "OG001", "value": "330"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "8.3", "spread": "1.41"}, {"groupId": "OG001", "value": "12.0", "spread": "1.41"}]}]}, {"title": "Total Daily Insulin Dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "316"}, {"groupId": "OG001", "value": "321"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "12.1", "spread": "1.93"}, {"groupId": "OG001", "value": "17.3", "spread": "1.92"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) Regimen Inconvenience Domain Score at Week 26", "description": "ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. The questionnaire measures satisfaction from the following 5 domains: Inconvenience of Regimen, Lifestyle Flexibility, Glycemic Control, Hypoglycemic Control, and Insulin Delivery Device. Data presented are the transformed overall score on a scale of 0-100, where higher scores indicate better treatment satisfaction.\n\nChange from baseline in ITSQ regimen inconvenience domain score was calculated using the ANCOVA model with strata (pooled country, type of basal insulin, number of prandial doses at study entry, and HbA1c stratum), and treatment as fixed effects and baseline as covariate. The analysis included data prior to permanent discontinuation of study drug.", "populationDescription": "All randomized participants with baseline and post-baseline data. Missing endpoints were imputed by applying the Last Observation Carried Forward (LOCF) method to post-baseline data. As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, Week 26", "groups": [{"id": "OG000", "title": "Insulin Lispro (Humalog)", "description": "Insulin lispro given SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}, {"id": "OG001", "title": "LY900014", "description": "LY900014 given subcutaneously (SC) with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "319"}, {"groupId": "OG001", "value": "319"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "1.36"}, {"groupId": "OG001", "value": "-2.4", "spread": "1.37"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in ITSQ Lifestyle Flexibility Domain Score at Week 26", "description": "ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. The questionnaire measures satisfaction from the following 5 domains: Inconvenience of Regimen, Lifestyle Flexibility, Glycemic Control, Hypoglycemic Control, and Insulin Delivery Device. Data presented are the transformed overall score on a scale of 0-100, where higher scores indicate better treatment satisfaction.\n\nChange from baseline in ITSQ lifestyle flexibility domain score was calculated using the ANCOVA model with strata (pooled country, type of basal insulin, number of prandial doses at study entry, and HbA1c stratum), and treatment as fixed effects and baseline as covariate. The analysis included data prior to permanent discontinuation of study drug.", "populationDescription": "All randomized participants with baseline and post-baseline data. Missing endpoints were imputed by applying the LOCF method to the post-baseline data. As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, Week 26", "groups": [{"id": "OG000", "title": "Insulin Lispro (Humalog)", "description": "Insulin lispro given SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily."}, {"id": "OG001", "title": "LY900014", "description": "LY900014 given subcutaneously (SC) with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "319"}, {"groupId": "OG001", "value": "319"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.4", "spread": "1.60"}, {"groupId": "OG001", "value": "0.2", "spread": "1.60"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With HbA1c <7%", "description": "Number of participants with HbA1c \\<7% at Week 26.", "populationDescription": "All participants with baseline and one post-baseline observation while on study drug. As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Insulin Lispro (Humalog)", "description": "Insulin lispro given SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}, {"id": "OG001", "title": "LY900014", "description": "LY900014 given subcutaneously (SC) with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "320"}, {"groupId": "OG001", "value": "316"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "168"}, {"groupId": "OG001", "value": "184"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Baseline up to 30 Weeks", "description": "All randomized participants.", "eventGroups": [{"id": "EG000", "title": "Insulin Lispro (Humalog) Lead-In", "description": "100 U/mL Insulin lispro given SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.", "deathsNumAffected": 0, "deathsNumAtRisk": 750, "seriousNumAffected": 13, "seriousNumAtRisk": 750, "otherNumAffected": 44, "otherNumAtRisk": 750}, {"id": "EG001", "title": "Insulin Lispro (Humalog)", "description": "100 U/mL Insulin lispro given SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.", "deathsNumAffected": 1, "deathsNumAtRisk": 337, "seriousNumAffected": 26, "seriousNumAtRisk": 337, "otherNumAffected": 60, "otherNumAtRisk": 337}, {"id": "EG002", "title": "LY900014", "description": "100 U/mL LY900014 SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.", "deathsNumAffected": 2, "deathsNumAtRisk": 336, "seriousNumAffected": 26, "seriousNumAtRisk": 336, "otherNumAffected": 79, "otherNumAtRisk": 336}, {"id": "EG003", "title": "Insulin Lispro (Humalog) Lead-In Maximum Extended Enrollment", "description": "100 U/mL Insulin lispro (Humalog) SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.", "deathsNumAffected": 0, "deathsNumAtRisk": 183, "seriousNumAffected": 3, "seriousNumAtRisk": 183, "otherNumAffected": 12, "otherNumAtRisk": 183}, {"id": "EG004", "title": "Insulin Lispro (Humalog) Maximum Extended Enrollment (MEE)", "description": "100 U/mL Insulin lispro (Humalog) SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.", "deathsNumAffected": 0, "deathsNumAtRisk": 82, "seriousNumAffected": 4, "seriousNumAtRisk": 82, "otherNumAffected": 8, "otherNumAtRisk": 82}, {"id": "EG005", "title": "LY900014 (MEE)", "description": "100 U/mL LY900014 SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.", "deathsNumAffected": 0, "deathsNumAtRisk": 82, "seriousNumAffected": 2, "seriousNumAtRisk": 82, "otherNumAffected": 5, "otherNumAtRisk": 82}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Coronary artery stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Eye haemorrhage", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Papilloedema", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Sudden death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Bile duct stone", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Drug hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Empyema", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Eye infection viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Osteomyelitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Pyelonephritis acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Septic shock", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Concussion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Heat stroke", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Ligament sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 82}]}, {"term": "Multiple fractures", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Spinal compression fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Blood potassium decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 4, "numAffected": 3, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 82}]}, {"term": "Shock hypoglycaemic", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Lumbar spinal stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Clear cell renal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Meningioma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Renal neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Carpal tunnel syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Hypoglycaemic coma", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Lumbar radiculopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Ureteric compression", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Acute pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Acute respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Bronchitis chronic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Laryngeal disorder", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Diabetic ulcer", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Intermittent claudication", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Peripheral arterial occlusive disease", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Peripheral artery stenosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Peripheral vascular disorder", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 11, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 10, "numAffected": 10, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 12, "numAffected": 11, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 5, "numAffected": 5, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 25, "numAffected": 23, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 47, "numAffected": 38, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 56, "numAffected": 47, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 7, "numAffected": 7, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 4, "numAffected": 4, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 5, "numAffected": 5, "numAtRisk": 82}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 13, "numAtRisk": 750}, {"groupId": "EG001", "numEvents": 21, "numAffected": 20, "numAtRisk": 337}, {"groupId": "EG002", "numEvents": 29, "numAffected": 27, "numAtRisk": 336}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 183}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 82}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "As pre-specified in the analysis plan, outcome measures will not be reported for the Maximum Extended Enrollment (ME2) arms/groups but only for the main global study arms/groups."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Chief Medical Officer", "organization": "Eli Lilly and Company", "email": "ClinicalTrials.gov@lilly.com", "phone": "800-545-5979"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2017-05-19", "uploadDate": "2020-03-11T10:59", "filename": "Prot_000.pdf", "size": 22069200}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2018-07-24", "uploadDate": "2020-03-11T11:00", "filename": "SAP_001.pdf", "size": 3636893}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["China", "Slovenia"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000007328", "term": "Insulin"}, {"id": "C000557859", "term": "Insulin, Globin Zinc"}, {"id": "D000008687", "term": "Metformin"}, {"id": "D000069036", "term": "Insulin Glargine"}, {"id": "D000061268", "term": "Insulin Lispro"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "asFound": "Non-specific", "relevance": "HIGH"}, {"id": "M29802", "name": "Insulin Lispro", "asFound": "AUC", "relevance": "HIGH"}, {"id": "M347", "name": "Insulin Glargine", "asFound": "Interaction", "relevance": "HIGH"}, {"id": "M17768", "name": "Zinc", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Micro", "name": "Micronutrients"}]}}, "hasResults": true}